Back to top
more

Anika Therapeutics (ANIK)

(Delayed Data from NSDQ)

$8.77 USD

8.77
134,672

+0.13 (1.51%)

Updated Aug 4, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Techne (TECH) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Techne (TECH) delivered earnings and revenue surprises of 7% and 2.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for April 26th

by Zacks Equity Research

ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022

Zacks Equity Research

New Strong Sell Stocks for April 19th

by Zacks Equity Research

ANIK, APP, and ARCE have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2022.

Zacks Equity Research

New Strong Sell Stocks for April 7th

by Zacks Equity Research

AMPE, ANIK, and FAT have been added to the Zacks Rank #5 (Strong Sell) List on April 7, 2022.

Zacks Equity Research

New Strong Sell Stocks for April 4th

by Zacks Equity Research

AKU, ANIK, and AY have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2022.

Zacks Equity Research

New Strong Sell Stocks for March 28th

by Zacks Equity Research

ALIM, ANIK, and APPF have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2022

Zacks Equity Research

New Strong Sell Stocks for March 21st

by Zacks Equity Research

ARAY, AKU, and ANIK have been added to the Zacks Rank #5 (Strong Sell) List on March 21, 2022

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -149.56% and 99.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Horizon Therapeutics (HZNP) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 11.02% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alector (ALEC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alector (ALEC) delivered earnings and revenue surprises of -423.08% and 81.43%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Anika Therapeutics (ANIK) Tops Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of 144.44% and 8.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Anika Therapeutics (ANIK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Earnings Preview: Anika Therapeutics (ANIK) Q2 Earnings Expected to Decline

by Zacks Equity Research

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Anika Therapeutics (ANIK) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of 225.00% and 5.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for March 9th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Anika Therapeutics (ANIK) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -1000.00% and -2.40%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Rimmi Singhi headshot

Keep These 4 Toxic Stocks Away From Your Portfolio

by Rimmi Singhi

Just like selecting good and undervalued stocks on a regular basis can make you rich, identifying and proactively getting rid of toxic stocks is also crucial to maximizing portfolio returns.

Zacks Equity Research

Anika Therapeutics (ANIK) Surges: Stock Moves 6.6% Higher

by Zacks Equity Research

Anika Therapeutics (ANIK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Zacks Equity Research

New Strong Sell Stocks for November 9th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Anika (ANIK) delivered earnings and revenue surprises of -462.50% and -1.63%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Anika Therapeutics (ANIK) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

ANIK vs. ILMN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ANIK vs. ILMN: Which Stock Is the Better Value Option?

Zacks Equity Research

ANIK vs. NEO: Which Stock Is the Better Value Option?

by Zacks Equity Research

ANIK vs. NEO: Which Stock Is the Better Value Option?

Zacks Equity Research

ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ANIK vs. ALKS: Which Stock Is the Better Value Option?